Effects on Health Status in Patients Early Discharged After Primary Percutaneous Coronary Intervention (PCI)
Launched by HELSE STAVANGER HF · Nov 18, 2010
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
The safety and feasibility of early discharge of low-risk STEMI treated with thrombolysis or PPCI patients have previously been investigated. It is possible to identify a subset of patients with very low risk for subsequent cardiac events in the short-term, where prolonged hospital stay beyond three days does not alter the outcome. Early discharge have however, not been included in STEMI management guidelines formally. The effects of this discharge regimen on STEMI patients' health status (symptoms, functional capacity and quality of life) is not previously investigated. Shorter hospital st...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ST elevation acute myocardial infarction
- • Undergoing primary PCI
- Exclusion Criteria:
- • Zwolle low risk criteria score \>4
- • Re-infarction, post AMI ischemia.
- • Need for urgent repeat invasive procedures.
- • Non-cardiac complication (bleeding, stroke oa.) or concomitant diseases likely to increase length of hospital stay.
- • Patient or caring physician refuse to early discharge or study inclusion.
- • Early discharge impossible due to social, nursing or family reasons.
About Helse Stavanger Hf
Helse Stavanger HF is a leading healthcare organization based in Norway, dedicated to providing high-quality medical services and advancing clinical research. As a prominent sponsor of clinical trials, Helse Stavanger HF focuses on innovative therapeutic interventions across various medical fields, aiming to enhance patient care and outcomes. With a commitment to ethical research practices and collaboration with academic institutions, the organization plays a vital role in the development of new treatments and the improvement of healthcare standards in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stavanger, Rogaland, Norway
Patients applied
Trial Officials
Tor Melberg, MD PhD
Principal Investigator
Helse Stavanger HF
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials